On Thursday, Sanofi-Aventis reported its second-quarter net profit rose 7.6% to 2.48 billion euros, beating expectations. But the French drugmaker warned that earnings may fall for the full year, and it remained silent about its rumored plan to make a friendly bid for Genzyme.
Pharmaceutical firm Sanofi-Aventis is preparing a major acquisition in the U.S. worth $20 billion or more, according to Bloomberg, which cited five people with knowledge of the situation.
AstraZeneca shares surged by almost 9% Tuesday after the company scored a win in court regarding the patent for its cholesterol treatment, Crestor. The ruling means that AstraZeneca won't have to worry about generic competition for its multibillion-dollar statin until 2016.